Beta
ManageSearchChatDiscover
9798

The Effect Of Eicosapentanoic Acid Administration On Clinical Outcome Of Patients With Major Depression: A Pilot Study

Article

Last updated: 24 Dec 2024

OverviewSimilar Items

Subjects

-

Tags

-

Abstract

Background: Major depressive disorder (MDD) is a common brain disorder that affects approximately 10% of the world population and leads to significant disability. The current study was aimed to evaluate the impact of Omega3 PUFAs administration on the clinical outcome of patients with depression.
Patients and Methods: This prospective, randomized controlled study included a total of Forty-two patients who diagnosed with depression according to a strict inclusion and exclusion criteria, attending at the outpatient clinics of the Department of Psychiatry, Al-Zahraa University Hospital, Cairo, Egypt. Approval of the Ethical Research Committee of Faculty of Pharmacy, Ain Shams University (registration number 61), and a written informed consent from all the subjects were obtained. This study was conducted between February 2015 till August 2016. patients were randomly assigned to either; Group1; (intervention n=21); received the prescribed antidepressant + omega3 (2100mg) for 8 weeks, or Group 2; (control, n=21); received the prescribed antidepressant only for 8 weeks. Baseline evaluation and 8-week assessment included; patient demographic- data collection, history taking and clinical assessment of DSM-5 criteria & HAM-D score. Laboratory assessment included; complete blood picture (CBC), prothrombin time (PT), activated partial thromboplastin time (aPTT). Patients were followed up regularly every 2 weeks for 8 weeks for the occurrence of side effects due to antidepressants/ Omega 3 and compliance with medications.
Results: The 2 groups were comparable at baseline. The test group showed a significant improvement in the HAMD score from baseline values and versus the control. There was no significant difference in the reported side effects between the 2 groups.
Conclusion: Omega -3 PUFAs administration at a dose of 2100 (EPA1350 mg/ , DHA 600 mg/ 150 mg other omega 3 FA) for 8 weeks, improved depression symptoms and was well tolerated.

DOI

10.21608/ejhm.2018.9798

Keywords

Omega-3 PUFAs, depression, HAMD, EPA/DHA

Authors

First Name

El Baz

Last Name

A.H.

MiddleName

-

Affiliation

Department of Clinical Pharmacy, Faculty of pharmacy,Ahram Canadian University

Email

elbaz_alaa@yahoo.com

City

-

Orcid

-

First Name

Zaki

Last Name

M.A

MiddleName

-

Affiliation

Department of Clinical Pharmacy, Faculty of pharmacy,Ahram Canadian University

Email

-

City

-

Orcid

-

First Name

El Wakeel

Last Name

L.M.

MiddleName

-

Affiliation

Department of Clinical Pharmacy, Faculty of Pharmacy, Ain Shams University

Email

-

City

-

Orcid

-

First Name

El-Shafie

Last Name

T. M

MiddleName

-

Affiliation

Department of Psychiatry, Faculty of Medicine, Al Azhar University

Email

-

City

-

Orcid

-

Volume

72

Article Issue

6

Related Issue

1884

Issue Date

2018-07-01

Receive Date

2018-07-28

Publish Date

2018-07-01

Page Start

4,666

Page End

4,672

Print ISSN

1687-2002

Online ISSN

2090-7125

Article File

EJHM_Volume 72_Issue 6_Pages 4666-4672.pdf

PDF . 300.7kB

Link

https://ejhm.journals.ekb.eg/article_9798.html

Detail API

https://ejhm.journals.ekb.eg/service?article_code=9798

Order

15

Type

Original Article

Type Code

606

Publication Type

Journal

Publication Title

The Egyptian Journal of Hospital Medicine

Publication Link

https://ejhm.journals.ekb.eg/

MainTitle

The Effect Of Eicosapentanoic Acid Administration On Clinical Outcome Of Patients With Major Depression: A Pilot Study

Details

Type

Article

Created At

22 Jan 2023